Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 4 May 2022 New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods Non-regulated information 25 April 2022 Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Non-regulated information 21 April 2022 Biocartis Announces Presentation of First Prospective Validation Study Data of Merlin Test by Partner SkylineDx at EADO 2022 Conference Non-regulated information 8 February 2022 Biocartis and Ophiomics to Collaborate on Liver Cancer Test Non-regulated information 25 January 2022 Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes Non-regulated information 9 December 2021 Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant Non-regulated information 30 November 2021 SeptiCyte® RAPID Receives 510(k) clearance by US FDA Non-regulated information 16 November 2021 New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer Non-regulated information 23 September 2021 Biocartis Announces Restart of its High-Throughput Cartridge Manufacturing Line Non-regulated information 2 September 2021 Biocartis Launches Idylla™ SARS-CoV-2/Flu/RSV Panel Non-regulated information Pagination First page « First Previous page ‹‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page ›› Last page Last »